Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Add filters

Year range
Chinese Journal of Lung Cancer ; (12): 319-324, 2023.
Article in Chinese | WPRIM | ID: wpr-982162


Lung cancer is the most common in incidence and mortality worldwide. With the development of next generation sequencing (NGS) detection technology, more and more patients with rare anaplastic lymphoma kinase (ALK) fusion mutations were detected. A case of advanced lung adenocarcinoma with rare COX7A2L-ALK (C2:A20) fusion detected by NGS was reported in Peking Union Medical College Hospital, and all cases with rare ALK fusion mutations were searched from medical datebase from January 1, 2014 to March 31, 2021, to investigate the treatment of rare ALK fusion mutations with ALK inhibitors. The best response of the patient was assessed as partial response (PR) with Ceritinib treatment. By literature review, 22 cases of rare ALK fusion were reported in 19 articles. Combined with this case, 23 cases were analyzed. The objective response rate (ORR) was 82.6% (19/23) and disease control rate (DCR) was 95.7% (22/23) for rare ALK fusions patients treated with ALK inhibitors. Lung adenocarcinoma patients with rare ALK fusion could benefit from ALK inhibitors.

Humans , Anaplastic Lymphoma Kinase/genetics , Lung Neoplasms/diagnosis , Crizotinib , Adenocarcinoma of Lung/genetics , Protein Kinase Inhibitors/pharmacology , Oncogene Proteins, Fusion/genetics
Chinese Journal of Lung Cancer ; (12): 501-505, 2022.
Article in Chinese | WPRIM | ID: wpr-939738


Clinical trials of anti-tumor drugs is not only the important way to develop new drugs, but also the most advanced treatment methods for malignant tumors, bringing survival benefits to patients. There are a large number of new anti-tumor drug clinical trials for lung cancer patients, covering a wide variety of anti-tumor drugs, and with rapid progress and high efficiency of clinical transformation. These trials could not be carried out successfully without the joint efforts of the research team, in which the research nurses also played a role that should not be underestimated. Combined with the work content of clinical research nurses, this paper introduced the post management, role function, core competence and career development prospect of clinical research nurses in the process of carrying out clinical trial of lung cancer drugs in detail. In order to provide reference for more medical institutions to carry out related work, and promote the further development of clinical research nurses to standardization and specialization.

Humans , Antineoplastic Agents/therapeutic use , Lung Neoplasms/drug therapy
Chinese Journal of Lung Cancer ; (12): 377-383, 2021.
Article in Chinese | WPRIM | ID: wpr-880272


The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development.

Chinese Journal of Practical Nursing ; (36): 993-997, 2016.
Article in Chinese | WPRIM | ID: wpr-492517


Objective To evaluate the reliability and validity of the Chinese version of A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF), and discuss the applicability of this tool among interstitial lung disease (ILD) patients. Methods 128 patients with ILD were selected from the respiratory department of Peking Union Medical College Hospital, and a convenient sampling method was adopted. Test-retest reliability cofficient, Cronbach αinternal consistency, content validity, criterion related validity were used to evaluate the reliability and validity of the Chinese version of ATAQ-IPF. Results Among first 15 recruited patients, the localized ATAQ-IPF had good test-retest reliability, the intraclass correlation coefficient(ICC) calculation was 0.95 (P<0.05). The evaluation of all 128 patients showed excellent internal consistency with the Cronbach α was 0.96,Cronbach α values of each dimension were 0.60-0.93. The scale level content validity index (S-CVI) was 0.80;The item level content validity index (I-CVI)were 0.78-1.00,which proved good validity. The score between the Chinese version of ATAQ-IPF and St. George Respiratory Questionnaire(SGRQ) showed a significant correlation (r=0.69, P<0.01). Criterion related validity was good. 128 patients were grouped according to the entity and the degree of dyspnea,evaluated the quality of life. There was a significant difference between idiopathic pulmonary fibrosis (IPF) and non-IPF patients(t=2.99, P < 0.01).Also the differences between different degrees of dyspnea were statistically significant(t=16.05, P<0.01). Conclusions The Chinese version of ATAQ-IPF retains good reliability and validity, and is qualified to assess the quality of life among ILD patients.